ストックスクリーナーアプリを入手
1.4976
2.00%
0.0024
前日終値:
$1.50
開ける：
$1.55
24時間の取引高:
144.31K
Relative Volume:
0.17
時価総額：
$34.42M
収益：
-
当期純損益:
$-8.09M
株価収益率:
-3.4396
EPS:
-0.4354
ネットキャッシュフロー:
$-7.37M
1週間 パフォーマンス:
+10.87%
1か月 パフォーマンス:
+10.87%
6か月 パフォーマンス:
+23.39%
1年 パフォーマンス:
+10.87%
1日の値動き範囲:
$1.4976
$1.58
1週間の範囲:
$1.30
$1.58
52週間の値動き範囲:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Compare NNVC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.4976 | 31.72M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
518.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.52 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.05 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.43 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.49 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | 開始されました | Alliance Global Partners | Buy |
| 2015-02-11 | 開始されました | Midtown Partners | Strong Buy |
NanoViricides Inc (NNVC) 最新ニュース
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
FDA rare pediatric disease designation could speed a measles drug review - Stock Titan
[EFFECT] NANOVIRICIDES, INC. SEC Filing - Stock Titan
NanoViricides, Inc. Actuals & Estimates (MUN:NV3P) - TradingView
NanoViricides, Inc. Actuals & Estimates (AMEX:NNVC) - TradingView
symbol__ Stock Quote Price and Forecast - CNN
NanoViricides, Inc. Actuals & Estimates (LS:A2PSNF) - TradingView
NNVC Forecast — Price Target — Prediction for 2027 - TradingView
A2PSNF Forecast — Price Target — Prediction for 2027 - TradingView
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan - Yahoo Finance
NanoViricides Inc (NNVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
NanoViricides Inc (NNVC) Institutional Confidence - TradingKey
NanoViricides Ships NV-387 to DRC for Phase II MPox Trial - MEXC
NanoViricides sends oral NV-387 to Congo for Phase II trial prep - Stock Titan
NanoViricides Inc (NNVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Inc (NNVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial for Oral Antiviral NV-387 - citybuzz -
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NNVC Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentEarnings Expansion Phase - newsline.com
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatmentwith Superior Oral Administration and Escape Resistance Features Over Antibodies - ACCESS Newswire
NanoViricides pushes chewable Ebola drug trial as Congo outbreak escalates - Stock Titan
NanoViricides Files for $50 Million Mixed Shelf Offering - Moomoo
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides (NNVC) Edges Lower Within Narrow Trading RangePre-Earnings Momentum - newsline.com
NanoViricides (NNVC) Slides 3.6% as Selling Pressure IntensifiesInstitutional Buy Signals - The Legal Advocate
NanoViricides (NNVC) Retreats 4.3%, Nears Critical Support at $1.69AAII Bullish - thelegaladvocate.com
Ebola Global Health Emergency Needs a Broad-Spectrum DrugNV-387 is a Strong Potential Candidate, Says NanoViricides - ACCESS Newswire
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
Nanoviricides(NNVC) Stock Options Chain | Quotes & News - Moomoo
NanoViricides (NNVC) Surges 15.9% as Speculative Buying Drives Shares Above $1.75MA Cross Alert - The Legal Advocate
NanoViricides (NNVC) Surges 13.6% as Stock Approaches Key ResistanceSwing Trade Setups - The Legal Advocate
NNVC Stock Gains Attention As NV-387 Targets Ebola And Measles - StocksToTrade
NNVC Stock Draws Traders As NV-387 Targets Ebola, Measles - timothysykes.com
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides - ACCESS Newswire
NNVCNanoViricides Inc Stock Price and Quote - Finviz
Contact | Statesman-Examiner - FinancialContent
Rare Ebola strain has no treatment; NanoViricides lines up oral NV-387 - Stock Titan
NanoViricides Inc. (NNVC) Q1 2026 Earnings: Narrower Loss Drives Positive Stock ReactionEarnings Beat Streak - newsline.com
Shelton biotech NanoViricides raises $2M in stock offering - Hartford Business Journal
A. G. P. Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak - TipRanks
NanoViricides Completes $2 Million Registered Direct Offering - TipRanks
NanoViricides Raises $2 Million in Registered Direct Offering With Common and Pre-Funded Warrants - TradingView
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug - citybuzz -
NanoViricides closes $2M direct offering - Yahoo! Finance Canada
NanoViricides, Inc - Reuters
NanoViricides Inc (NNVC) 財務データ
収益
当期純利益
現金流量
EPS
1.95%
0.07%
大文字化:
|
ボリューム (24 時間):